AI assistant
Insight Molecular Diagnostics Inc. — Director's Dealing 2018
Jun 4, 2018
34238_dirs_2018-06-04_7fbf6b45-0000-431c-af70-94aeffaba619.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-05-23
Reporting Person: MECHEM KRISTINE C. (VP of Marketing)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-23 | Option to Purchase Common Stock | $2.35 | A | 125000 | Acquired | 2028-05-22 | Common Stock (125000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option to Purchase Common Stock | $4.70 | 2027-02-16 | Common Stock (67500) | 67500 | Direct |
| Option to Purchase Common Stock | $3.06 | 2026-02-15 | Common Stock (60000) | 60000 | Direct |
| Option to Purchase Common Stock | $3.16 | 2025-08-03 | Common Stock (100000) | 100000 | Direct |
Footnotes
F1: These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
F2: One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
F3: One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
F4: One quarter of the options vested on August 3, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.